Defining the role of Microphthalmia-associated Transcription Factor (MITF) in melanoma heterogeneity by real-time cell cycle imaging [ 2015 - 2018 ]

Research Grant

Researchers: Prof Nikolas Haass (Principal investigator) ,  A/Pr Helmut Schaider ,  Prof Brian Gabrielli

Brief description Metastatic melanoma is highly therapy-resistant. Modern targeted therapy is promising but suffers from rapid onset of drug resistance. Tumours consist of zones of fast growing cells next to zones of dormant cells. This tumour heterogeneity is one of the reasons for cancer drug resistance, as cells in different growth states respond differently to drugs. By understanding the causes of tumour heterogeneity we will set the basis for innovative clinical approaches against this devastating disease.

Funding Amount $AUD 613,705.08

Funding Scheme Project Grants

Notes Standard Project Grant